Constrained Peptide Drugs Market Size, Share Report, Analysis, Trends, Growth 2032

Constrained Peptide Drugs Industry Prospective:

The global constrained peptide drugs market size was worth around USD 1,243.56 million in 2023 and is predicted to grow to around USD 4,374.69 million by 2032 with a compound annual growth rate (CAGR) of roughly 15.00% between 2024 and 2032.

Request Free Sample

Constrained Peptide Drugs Market: Overview

Constrained peptide drugs are produced using peptides with a short amino chain. Constrained peptides belong to a new class of peptide molecules. The supermolecular structure of constrained peptide drugs is controlled through intramolecular covalent bonds. The main purpose of developing drugs made of constrained peptides is to impart physicochemical and biochemical properties that are superior to ordinary counterparts. In recent times, industrial and research-based applications of constrained peptides have reached new levels since the substance has shown superior performance in terms of medicinal drugs. Research indicates that constrained peptide drugs have a high potential to deliver the best properties of small molecules and antibodies. However, the industry is relatively new and does not enjoy the perks of mature drugs that have long existed in the pharmaceutical industry. Scientists and the research community are working toward developing more effective constrained peptide drugs for applications in treating conditions with fatality rates or diseases with no effective cure. Constrained peptide drugs offer several advantages over traditional peptides that are known to have specific limitations including limited stability. Constrained peptides and drugs made using these modified substances generally showcase higher stability and selectivity thus making them highly versatile in terms of end-use applications. During the forecast period, the industry for constrained peptide drugs can expect high growth avenues while also dealing with specific challenges and limitations.

Key Insights:

• As per the analysis shared by our research analyst, the global constrained peptide drugs market is estimated to grow annually at a CAGR of around 15.00% over the forecast period (2024-2032)
• In terms of revenue, the globally constrained peptide drugs market size was valued at around USD 1,243.56 million in 2023 and is projected to reach USD 4,374.69 million, by 2032.
• The market is projected to grow at a significant rate due to the growing investments in novel drug research and development
• Based on the application, the institutes of biology segment is growing at a high rate and will continue to dominate the global market as per industry projection
• Based on the type, the cyclic peptides segment is anticipated to command the largest market share
• Based on region, North America is projected to dominate the global market during the forecast period

Request Free Sample

Constrained Peptide Drugs Market: Growth Drivers

Growing investments in novel drug research and development may aid a higher market growth rate

The global constrained peptide drugs market is expected to grow due to the increasing investments in the research and development of novel drugs and treatment processes. Against the backdrop of an ever-increasing burden on the global healthcare infrastructure, the need for developing effective treatments and drugs for treating highly fatal or contagious conditions has gained extensive momentum. Additionally, the drug research community is also working toward studying diseases or conditions that may impact the general population in the future. For instance, the latest mutation in the original coronavirus is termed KP.2, also known as FLiRT. KP.2 has been linked by researchers to the increasing number of COVID-19 cases across major countries including the UK and USA. In January 2024, the World Health Organization (WHO) informed the general public about Disease X. As per the international healthcare agency, Disease X is a disease of the future and can be 20 times more impactful than COVID-19. In the meanwhile, drug developers are constantly investing in developing new drugs or treatment plans for diseases that cannot be cured or treated with currently available medicines. In January 2024, Glenmark Pharmaceuticals announced the launch of a biosimilar variant of liraglutide which is used for lowering blood sugar levels in patients with type 2 diabetes. The new launch is called Glucagon-like peptide receptor agonist (GLP-1RA) and it performs by activating GLP-1 receptors present in the pancreas thus aiding reduction in glucagon release. Moreover, the increasing investments toward the construction of state-of-the-art technologies equipped research centers will be helpful in developing constrained peptide drugs. For instance, in March 2023, Evonik, a leading pharmaceutical company, commenced the construction of a new research facility worth USD 220 million. The new unit will be dedicated to research in pharmaceutical specialty lipids.

Growing cases of cancer to promote higher research in the industry

The globally constrained peptide drugs market will benefit from the increasing number of cancer cases worldwide. Cancer is one of the leading causes of medically-induced deaths globally impacting millions of people globally. Constrained peptide drugs have garnered the attention of the global medical community as a source of potential treatment for several types of cancer. Targeted peptides have been widely used as a part of cancer therapeutics for targeting receptors on cancer cells. These peptides do not have any negative impact on healthy tissues thus ensuring elimination of only affected cells.

Constrained Peptide Drugs Market: Restraints

Nascent stage of the industry will work against the market’s growth rate

The global industry for constrained peptide drugs will be restricted since the market is relatively new. Constrained peptide drugs are currently in their nascent stage of research and development as compared to other drugs. The global pharmaceutical industry is currently dominated by existing small-molecule drugs and biologics including monoclonal antibodies (mAbs) and fusion proteins. These drug types have been circulating in the market and are widely accepted among medical professionals for practical applications thus limiting the growth prospects for constrained peptide drugs.

Constrained Peptide Drugs Market: Opportunities

Increase in access to medical care worldwide may generate higher growth opportunities for the industry

The global constrained peptide drugs market is projected to generate growth opportunities due to the increasing access to medical care among the general population. Rise in income, higher disposable income, and greater awareness about the benefits of healthcare insurance have allowed more people to get treated for serious conditions without getting overburdened with the cost of treatment. In addition to this, national healthcare schemes have reached more people in the last few years. In 2023, reports emerged suggesting that South Africa was looking toward developing a national healthcare scheme as the region continued to face sharp increases in the number of patients suffering from several conditions. Furthermore, the emerging segment of telemedicine and growing use of advanced technologies such as artificial intelligence (AI) and machine learning (ML) for diagnosing medical conditions has helped the global healthcare system reach more patients thus creating future growth scope for constrained peptide drugs.

Surging demand for personalized medical care could trigger higher demand for constrained peptide drugs

Personalized medical care is an evolving segment of the medicine industry that deals with developing medical intervention policies depending on the genetic profile of the patient. Personalized medicine is significantly different from generic medical care since the latter represents using the same set of treatment protocols for all patients irrespective of their genetic makeup. In recent times, the demand and awareness around personalized medicine have soared resulting in and is expected to continue the same trend in the future thus creating growth scope for the globally constrained peptide drugs that can be formulated to treat medical conditions in patients depending on the genetic attributes.

Constrained Peptide Drugs Market: Challenges

High cost of investment and lack of infrastructure could challenge the market expansion rate

The global constrained peptide drugs industry will face critical challenges in the coming years due to the high cost of investment associated with the development and commercial distribution of novel drugs such as drugs made using constrained peptides. In addition to this, the infrastructure supporting the development of constrained peptide drugs is extremely weak unlike other systems supporting the production of other drugs.

Constrained Peptide Drugs Market: Segmentation

The global constrained peptide drugs market is segmented based on application, type, and region.

Based on the application, the global market segments are institutes of biology, hospitals, and others. In 2023, the highest growth was observed in the institutes of biology segment led by the growing research in the development of constrained peptide drugs. These facilities are equipped with essential technologies required for extensive research on the development of modified peptide drugs. The surging construction of an advanced institute of biology will help the segment flourish. An increase in patient footfall across global hospitals may contribute to the revenue in the hospitals segment. In 2023, the global hospital services industry generated a revenue of more than USD 12 trillion.

Based on the type, the global industry segments are disulfide-rich peptides (DRPs) and cyclic peptides. In 2023, the highest revenue was registered in the cyclic peptides segment. These variants have cyclic structure and they also have high natural abundance. Cyclic peptides are comparatively easier to produce as compared to disulfide-rich peptides (DRPs). The surge in novel drug development will promote higher segmental revenue. In 2023, the global drug discovery market was valued at USD 60.5 billion.

Constrained Peptide Drugs Market Scope

Constrained Peptide Drugs Market: Regional Analysis

North America to reign over other regions during the forecast period

The global constrained peptide drugs market is led by North America. In 2023, it was the highest revenue-generating region and is expected to deliver the same growth trend during the forecast period. The US region will help the region flourish as it is home to the largest number of pharmaceutical companies. As per official reports, the US contributes to over one-third of the global pharmaceutical industry driven by firms such as Johnson & Johnson, Eli Lilly and Co., Pfizer Inc., AbbVie Inc., and others. The regional pharmaceutical companies are heavy investors in novel drug development processes. The growing approval by the US Food & Drugs Administration (FDA) may further contribute to the regional growth revenue. Europe is expected to deliver high growth during the forecast period. Europe is witnessing higher healthcare expenditure as the regional demand for quality healthcare is on the rise. By 2027, Europe will witness an investment of €60 billion to be used across prevention, innovation, health digitalization, and infrastructure. Asia-Pacific has been growing at a steady rate. China, India, and Japan will be delivering higher revenue. The growing patient rate in China and India may impact the regional market revenue.

Constrained Peptide Drugs Market: Competitive Analysis

The global constrained peptide drugs market is led by players like:

• Union Chimique Belge S.A. (UCB)
• Aileron Therapeutics Inc.
• Zealand Pharma
• Bio-Synthesis Inc.
• Spexis AG
• Bicycle Therapeutics plc
• Circle Pharma
• Creative Peptides
• PeptiDream Inc.
• Pepticom Ltd.
• Protagonist Therapeutics Inc.
• Chugai Pharmaceutical Co. Ltd.
• Biosynth (Pepscan)
• Santhera Pharmaceuticals
• CPC Scientific Inc.

The global constrained peptide drugs market is segmented as follows:

By Application

• Institutes of Biology
• Hospitals

By Type

• Disulfide-Rich Peptides (DRPs)
• Cyclic Peptides

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa